JP2017538680A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538680A5 JP2017538680A5 JP2017525120A JP2017525120A JP2017538680A5 JP 2017538680 A5 JP2017538680 A5 JP 2017538680A5 JP 2017525120 A JP2017525120 A JP 2017525120A JP 2017525120 A JP2017525120 A JP 2017525120A JP 2017538680 A5 JP2017538680 A5 JP 2017538680A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cancer
- recurrence
- therapeutic agent
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462075532P | 2014-11-05 | 2014-11-05 | |
| US62/075,532 | 2014-11-05 | ||
| PCT/US2015/059297 WO2016073759A1 (en) | 2014-11-05 | 2015-11-05 | Combination immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538680A JP2017538680A (ja) | 2017-12-28 |
| JP2017538680A5 true JP2017538680A5 (enExample) | 2018-12-13 |
| JP7305300B2 JP7305300B2 (ja) | 2023-07-10 |
Family
ID=55909820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525120A Active JP7305300B2 (ja) | 2014-11-05 | 2015-11-05 | 併用免疫療法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11236139B2 (enExample) |
| EP (1) | EP3215182B1 (enExample) |
| JP (1) | JP7305300B2 (enExample) |
| WO (1) | WO2016073759A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6141864B2 (ja) | 2011-12-01 | 2017-06-07 | ケモセントリックス，インコーポレイティド | Ｃｃｒ（４）アンタゴニストとしての置換アニリン |
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| JP7305300B2 (ja) | 2014-11-05 | 2023-07-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 併用免疫療法 |
| AU2016256911B2 (en) | 2015-05-07 | 2022-03-31 | Agenus Inc. | Anti-OX40 antibodies and methods of use thereof |
| EA035412B1 (ru) | 2015-05-29 | 2020-06-10 | Бристол-Майерс Сквибб Компани | Антитела к ox40 и их применение |
| SG10201912984WA (en) | 2015-12-02 | 2020-03-30 | Agenus Inc | Antibodies and methods of use thereof |
| TWI794171B (zh) * | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| IL292302B2 (en) * | 2016-05-20 | 2023-10-01 | Biohaven Pharm Holding Co Ltd | Use of glutamate modulating factors in cancer immunotherapy |
| HUE065176T2 (hu) | 2016-06-02 | 2024-05-28 | Ultimovacs Asa | Vakcina kombinációban immunellenõrzõpont inhibitorral felhasználásra rák kezelésében |
| JP7250674B2 (ja) * | 2016-08-08 | 2023-04-03 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療及び診断方法 |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| WO2019057808A1 (en) | 2017-09-21 | 2019-03-28 | University Of Copenhagen | PEPTIDES POTENTIATING CHEMOTAXY AND USES THEREOF |
| US20220177534A1 (en) * | 2018-05-10 | 2022-06-09 | The Regents Of The University Of California | Ccl21 and checkpoint inhibitors for the treatment of cancer |
| ES3064498T3 (enExample) * | 2018-08-29 | 2026-04-27 | Chemocentryx Inc | |
| CN113874013A (zh) * | 2019-03-26 | 2021-12-31 | 转化药物开发有限责任公司 | 治疗卵巢恶性横纹肌样瘤和高钙血症型卵巢小细胞癌的方法 |
| EP3999092A4 (en) * | 2019-07-17 | 2023-08-09 | The Regents of the University of California | Combination cancer therapy agents and methods |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| WO1991004282A1 (fr) | 1989-09-21 | 1991-04-04 | Idemitsu Kosan Co., Ltd. | Polymere et copolymere d'arylstyrene et procede de preparation de tels polymeres |
| WO1993000109A1 (en) | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Method of stimulating immune response using growth hormone |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| WO2002085286A2 (en) * | 2001-04-18 | 2002-10-31 | The Regents Of The University Of California | Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| WO2004072286A1 (ja) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | ヒトｐｄ−１に対し特異性を有する物質 |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| WO2009117566A1 (en) * | 2008-03-21 | 2009-09-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Chemokine gene-modified cells for cancer immunotherapy |
| CA2736829C (en) | 2008-09-12 | 2018-02-27 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| PL2342226T3 (pl) | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| NZ702392A (en) * | 2012-06-08 | 2017-03-31 | Aduro Biotech | Compositions and methods for cancer immunotherapy |
| LT3702373T (lt) | 2013-09-13 | 2022-11-10 | Beigene Switzerland Gmbh | Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai |
| JP7305300B2 (ja) | 2014-11-05 | 2023-07-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 併用免疫療法 |
| GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| JP6930992B2 (ja) | 2016-02-29 | 2021-09-01 | ファウンデーション・メディシン・インコーポレイテッド | 腫瘍変異負荷を評価するための方法及びシステム |
| JP2020516654A (ja) * | 2017-04-13 | 2020-06-11 | センティ バイオサイエンシズ インコーポレイテッド | 組み合わせがん免疫療法 |
| US20220177534A1 (en) | 2018-05-10 | 2022-06-09 | The Regents Of The University Of California | Ccl21 and checkpoint inhibitors for the treatment of cancer |
-
2015
- 2015-11-05 JP JP2017525120A patent/JP7305300B2/ja active Active
- 2015-11-05 US US15/524,740 patent/US11236139B2/en active Active
- 2015-11-05 WO PCT/US2015/059297 patent/WO2016073759A1/en not_active Ceased
- 2015-11-05 EP EP15856689.3A patent/EP3215182B1/en active Active
-
2022
- 2022-01-18 US US17/577,973 patent/US20220162279A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hilmi et al. | Immune therapies in pancreatic ductal adenocarcinoma: Where are we now? | |
| Van Limbergen et al. | Combining radiotherapy with immunotherapy: the past, the present and the future | |
| Kershaw et al. | Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment | |
| JP2018502120A5 (enExample) | ||
| Van der Jeught et al. | Targeting the tumor microenvironment to enhance antitumor immune responses | |
| Procaccio et al. | Immunotherapy in gastrointestinal cancers | |
| Heindryckx et al. | Targeting the tumor stroma in hepatocellular carcinoma | |
| FI3728313T3 (fi) | Syövän yhdistelmähoito IAP-antagonistilla ja anti-PD-1-molekyylillä | |
| IL318946A (en) | Combinations of checkpoint inhibitors and cancer drugs | |
| JP2016527286A5 (enExample) | ||
| JP7146739B2 (ja) | 癌を処置するためのアデノウイルスとチェックポイント阻害剤の組合せ | |
| JP2012196206A5 (enExample) | ||
| HK1249433A1 (zh) | 含有mk2抑制剂肽的组合物用於治疗非小细胞肺癌的用途 | |
| Haddad et al. | Using viral vectors to deliver local immunotherapy to glioblastoma | |
| JP2018023397A5 (enExample) | ||
| JP2019517508A5 (enExample) | ||
| Murthy et al. | Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy | |
| Rallis et al. | Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances | |
| Giavedoni et al. | Acne fulminans successfully treated with cyclosporine and isotretinoin | |
| Bolm et al. | Multimodal anti-tumor approaches combined with immunotherapy to overcome tumor resistance in esophageal and gastric cancer | |
| JP2022542802A5 (enExample) | ||
| Ji et al. | Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors | |
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| Shannon et al. | Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma | |
| Fatemi et al. | Emerging frontiers in colorectal cancer therapy: From targeted molecules to immunomodulatory breakthroughs and cell-based approaches |